← All peptides
verifiedBioGate · GREENGrade B

Tesamorelin

YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL

Stabilized GHRH(1-44) analog; FDA-approved to reduce excess abdominal visceral fat in HIV patients via pulsatile GH release.

trans-3-hexenoyl N-terminal
MW
5135.85
Length
44aa
Posterior
89.6%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · trans-3-hexenoyl N-terminal
PDA-V1 attestation

Cryptographic chain of custody.

Outer PDA hash
Inputs hash
Merkle root
TEE attestation
Protocol version
PDA-V1
Source
peptide-md
Model version
structure-fm-2026.04
Candidates emitted
6
Signed
2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with @peptide-md/verifier.
Verify this attestation →Download dossier (PDF)Compare with…
Real-world evidence

Cohort-attested outcomes.

Cohorts
5
Participants
429
Mean Δ
-0.88
Δ HRV ms (8-week) · 95% CI [-1.64, -0.11]
IPNFT - Not minted

This peptide is not currently represented as an IPNFT. Cohort outcomes feed back into the unminted pool.

Citations

Source literature.

Grade A2007 · N Engl J Med

Metabolic effects of a growth hormone-releasing factor in patients with HIV

Falutz J et al.

PMID 18046029